Cargando…

Correction to: Safety and efficacy of ripasudil in Japanese patients with glaucoma or ocular hypertension: 12-month interim analysis of ROCK-J, a post-marketing surveillance study

Detalles Bibliográficos
Autores principales:	Tanihara, Hidenobu, Kakuda, Takahiko, Sano, Tetsuro, Kanno, Takashi, Gunji, Ryoji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7487738/ https://www.ncbi.nlm.nih.gov/pubmed/32887561 http://dx.doi.org/10.1186/s12886-020-01595-7

Ejemplares similares

Safety and efficacy of ripasudil in Japanese patients with glaucoma or ocular hypertension: 12-month interim analysis of ROCK-J, a post-marketing surveillance study
por: Tanihara, Hidenobu, et al.
Publicado: (2020)

Safety and Efficacy of Ripasudil in Japanese Patients with Glaucoma or Ocular Hypertension: 3-month Interim Analysis of ROCK-J, a Post-Marketing Surveillance Study
por: Tanihara, Hidenobu, et al.
Publicado: (2019)

Long-Term Intraocular Pressure-Lowering Effects and Adverse Events of Ripasudil in Patients with Glaucoma or Ocular Hypertension over 24 Months
por: Tanihara, Hidenobu, et al.
Publicado: (2022)

Intraocular pressure-lowering effects of ripasudil in uveitic glaucoma, exfoliation glaucoma, and steroid-induced glaucoma patients: ROCK-S, a multicentre historical cohort study
por: Futakuchi, Akiko, et al.
Publicado: (2020)

Effects of K-115 (Ripasudil), a novel ROCK inhibitor, on trabecular meshwork and Schlemm’s canal endothelial cells
por: Kaneko, Yoshio, et al.
Publicado: (2016)

Crossover Randomized Study of Pharmacologic Effects of Ripasudil–Brimonidine Fixed-Dose Combination Versus Ripasudil or Brimonidine
por: Tanihara, Hidenobu, et al.
Publicado: (2023)

Ripasudil in a Model of Pigmentary Glaucoma
por: Wang, Chao, et al.
Publicado: (2020)

Role of ripasudil as an adjunct treatment in the management of pseudoexfoliative glaucoma
por: Mohapatra, Sumita, et al.
Publicado: (2023)

Interim Results of Post-Marketing Observational Study of Omidenepag Isopropyl for Glaucoma and Ocular Hypertension in Japan
por: Nakazawa, Toru, et al.
Publicado: (2022)

Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus: Results of 24‐month interim analysis of a long‐term post‐marketing study (J‐STEP/LT)
por: Utsunomiya, Kazunori, et al.
Publicado: (2020)

Ripasudil Hydrochloride Hydrate in the Treatment of Glaucoma: Safety, Efficacy, and Patient Selection
por: Kusuhara, Sentaro, et al.
Publicado: (2020)

Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real‐world practice: Results of 12‐month interim analysis of a long‐term post‐marketing surveillance study (J‐STEP/LT)
por: Utsunomiya, Kazunori, et al.
Publicado: (2019)

Safety and efficacy of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real‐world clinical practice: Results of 3‐month interim analysis of a long‐term post‐marketing surveillance study (J‐STEP/LT)
por: Utsunomiya, Kazunori, et al.
Publicado: (2019)

Additive Intraocular Pressure-Lowering Effects of Ripasudil with Glaucoma Therapeutic Agents in Rabbits and Monkeys
por: Kaneko, Yoshio, et al.
Publicado: (2017)

Effects of Ripasudil on Open-Angle Glaucoma after Circumferential Suture Trabeculotomy Ab Interno
por: Sato, Tomoki, et al.
Publicado: (2021)

Japanese study of tofogliflozin with type 2 diabetes mellitus patients in an observational study of the elderly (J‐STEP/EL): A 12‐week interim analysis
por: Utsunomiya, Kazunori, et al.
Publicado: (2016)

Increase in the OCT angiographic peripapillary vessel density by ROCK inhibitor ripasudil instillation: a comparison with brimonidine
por: Chihara, Etsuo, et al.
Publicado: (2018)

Safety, efficacy, and patient selection of ripasudil in patients with uncontrolled glaucoma with maximum conventional medical therapy
por: Jethva, Jignesh, et al.
Publicado: (2022)

Phase 3 Clinical Trial Comparing the Safety and Efficacy of Netarsudil to Ripasudil in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: Japan Rho Kinase Elevated Intraocular Pressure Treatment Trial (J-ROCKET)
por: Araie, Makoto, et al.
Publicado: (2023)

Effect of ripasudil on diabetic macular edema
por: Minami, Yoshiro, et al.
Publicado: (2019)

Ripasudil alleviated the inflammation of RPE cells by targeting the miR-136-5p/ROCK/NLRP3 pathway
por: Gao, Zhao, et al.
Publicado: (2020)

Comparison of intraocular pressure-lowering effects of ripasudil hydrochloride hydrate for inflammatory and corticosteroid-induced ocular hypertension
por: Yasuda, Mami, et al.
Publicado: (2017)

Safety and effectiveness of tofogliflozin in elderly Japanese patients with type 2 diabetes mellitus: A subanalysis of a post‐marketing study (J‐STEP/EL Study)
por: Kaku, Kohei, et al.
Publicado: (2019)

The ROCK Inhibitor Ripasudil Shows an Endothelial Protective Effect in Patients With Low Corneal Endothelial Cell Density After Cataract Surgery
por: Fujimoto, Hisataka, et al.
Publicado: (2021)

Ripasudil Attenuates Lipopolysaccharide (LPS)-Mediated Apoptosis and Inflammation in Pulmonary Microvascular Endothelial Cells via ROCK2/eNOS Signaling
por: Yang, Jianxin, et al.
Publicado: (2018)

Erratum in: The ROCK Inhibitor Ripasudil Shows an Endothelial Protective Effect in Patients With Low Corneal Endothelial Cell Density After Cataract Surgery
Publicado: (2021)

Responsiveness to ripasudil may be a potential outcome marker for selective laser trabeculoplasty in patients with primary open-angle glaucoma
por: Baba, Taro, et al.
Publicado: (2021)

Safety and effectiveness of tofogliflozin in elderly Japanese patients with type 2 diabetes mellitus: A post‐marketing study (J‐STEP/EL Study)
por: Utsunomiya, Kazunori, et al.
Publicado: (2017)

Topical ripasudil stimulates neuroprotection and axon regeneration in adult mice following optic nerve injury
por: Nishijima, Euido, et al.
Publicado: (2020)

Factors Influencing Aqueous Proinflammatory Cytokines and Growth Factors in Uveitic Glaucoma
por: Ohira, Saori, et al.
Publicado: (2016)

Topical Ripasudil for the Treatment of Primary Corneal Endothelial Degeneration in Dogs
por: Michalak, Sarah R., et al.
Publicado: (2022)

Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus treated in real‐world clinical practice: Results of a 36‐month post‐marketing surveillance study (J‐STEP/LT)
por: Utsunomiya, Kazunori, et al.
Publicado: (2020)

Long-Term Outcomes and Complications of Trabeculectomy for Secondary Glaucoma in Patients with Familial Amyloidotic Polyneuropathy
por: Kawaji, Takahiro, et al.
Publicado: (2014)

Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: interim analysis of post-marketing surveillance
por: Murai, Hiroyuki, et al.
Publicado: (2021)

The Influence of Phacoemulsification on Surgical Outcomes of Trabeculectomy with Mitomycin-C for Uveitic Glaucoma
por: Nishizawa, Asaho, et al.
Publicado: (2016)

Safety and Effectiveness of Natalizumab: First Report of Interim Results of Post-Marketing Surveillance in Japan
por: Saida, Takahiko, et al.
Publicado: (2017)

Ripasudil Endgame: Role of Rho-Kinase Inhibitor as a Last-Ditch-Stand Towards Maximally Tolerated Medical Therapy to a Patient of Advanced Glaucoma
por: Naik, Mayuresh, et al.
Publicado: (2021)

The Additive Effect of ROCK Inhibitor on Prostaglandin-Treated Japanese Patients with Glaucoma Indicating 15 mmHg and Under: ROCK U-15
por: Sakata, Rei, et al.
Publicado: (2021)

Intraocular pressure-lowering effects of Ripasudil: a potential outcome marker for Trabeculotomy
por: Goda, Erina, et al.
Publicado: (2019)

Crosslinking-Induced Corneal Endothelium Dysfunction and Its Protection by Topical Ripasudil Treatment
por: Wang, Xuemei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4rmcnd07jae2h3tdkgk0r6df4q